James Emmett Herndon II

Current research interests have application to the design and analysis of cancer clinical trials. Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).

Current Appointments & Affiliations

Professor of Biostatistics & Bioinformatics · 2022 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics

Member of the Duke Cancer Institute · 1988 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Financial toxicity of oral chemotherapy in patients with primary brain tumors.

Journal Article Neuro-oncology practice · February 2025 BackgroundCancer treatment costs continue to rise with the development of new agents. Financial toxicity is defined as the quantifiable costs associated with cancer and cancer treatment in addition to the patient's associated distress. This study' ... Full text Cite

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Journal Article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item Cite

Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastases.

Journal Article Neurooncol Pract · December 2024 BACKGROUND: Prognostic indices for patients with brain metastases (BM) are needed to individualize treatment and stratify clinical trials. Two frequently used tools to estimate survival in patients with BM are the recursive partitioning analysis (RPA) and ... Full text Link to item Cite

View All Publications

Education, Training & Certifications

University of North Carolina, Chapel Hill · 1988 Ph.D.

James Emmett Herndon II

Overview

Current Appointments & Affiliations

Recent Publications

Financial toxicity of oral chemotherapy in patients with primary brain tumors.

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastases.

Recent Grants

Enhancing the efficacy of Radiation Therapy for brainstem glioma by targeting ATM

ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas

Randomized Phase 2 (Ph2) clinical trial of Lerapolturev (previously known as PVSRIPO) in recurrent glioblastoma (rGBM)

Education, Training & Certifications